Literature DB >> 1873591

Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion.

R C Ash1, M M Horowitz, R P Gale, D W van Bekkum, J T Casper, E C Gordon-Smith, P J Henslee, H J Kolb, B Lowenberg, T Masaoka.   

Abstract

Results of 470 bone marrow transplants from related donors other than genotypically HLA-identical siblings (alternative related donors) were analysed to identify factors associated with transplant outcome and to determine whether T cell depletion improved results. As compared to 3648 transplant from HLA-identical siblings, alternative related donor transplants were associated with increased graft failure, increased acute graft-versus-host disease (GVHD), and lower disease-free survival. The likelihood of adverse outcome correlated with increasing donor-recipient HLA-disparity. In multivariate analysis of alternative related donor transplants, donor age greater than or equal to 30 years, (relative risk [RR] 1.7, p less than 0.006), intermediate and advanced leukemia (RR 1.5 and 1.6, p less than 0.01 and p less than 0.003), infection pretransplant (RR 1.7, p less than 0.005) and 2- and 3-locus donor-recipient HLA-disparity (RR 1.3, p less than 0.04) were associated with increased risks of treatment failure. The 2-year probability of leukemia-free survival after alternative related donor transplants (n = 43) with none of these adverse prognostic features was 44% (95% confidence interval 28-59%) compared to 56% (95% confidence interval 52-59%) for similar patients receiving HLA-identical sibling transplants (n = 868, univariate p less than 0.03). T cell depletion increased graft failure and decreased acute GVHD after alternative related donor transplants but did not improve leukemia-free survival.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873591

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  41 in total

1.  Using related donors other than genotypically HLA-matched siblings in allogeneic hematopoietic stem cell transplantation for hematologic disease: a single institution experience in Japan.

Authors:  Akira Tomonari; Tohru Iseki; Jun Ooi; Satoshi Takahashi; Koji Ishii; Tsutomu Takahashi; Motohiro Shindo; Fumitaka Nagamura; Kaoru Uchimaru; Hitomi Nagayama; Naoki Shirafuji; Arinobu Tojo; Kenzaburo Tani; Shigetaka Asano
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 2.  Separating antiviral and GVHD activities of donor T cells prior to bone marrow transplantation.

Authors:  Catherine T Jordan; John D Roback
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Progress in haploidentical stem cell transplantation.

Authors:  Ulas D Bayraktar; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-09       Impact factor: 5.742

Review 4.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

Review 5.  Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy.

Authors:  Piyanuch Kongtim; Dean A Lee; Laurence J N Cooper; Partow Kebriaei; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-11       Impact factor: 5.742

6.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 7.  HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.

Authors:  E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 8.  T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.

Authors:  A Bashey; S R Solomon
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

9.  Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Authors:  Johnnie J Orozco; Aimee Kenoyer; Ethan R Balkin; Ted A Gooley; Donald K Hamlin; D Scott Wilbur; Mark D Hylarides; Sofia H L Frost; Raya Mawad; Paul O'Donnell; Brenda M Sandmaier; Ephraim J Fuchs; Leo Luznik; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

Review 10.  Recent developments in HLA-haploidentical transplantations.

Authors:  Margaret Showel; Ephraim J Fuchs
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-22       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.